Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-01-28
DOI
10.1007/s10096-021-04397-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cross-resistance to cefiderocol and ceftazidime–avibactam in KPC β-lactamase mutants and the inoculum effect
- (2021) Claire Amaris Hobson et al. CLINICAL MICROBIOLOGY AND INFECTION
- Meropenem-vaborbactam as salvage therapy for ceftazidime-avibactam-, cefiderocol-resistant ST-512 Klebsiella pneumoniae producing KPC-31, a D179Y variant of KPC-3
- (2021) Giusy Tiseo et al. Open Forum Infectious Diseases
- Contribution of PER-Type and NDM-Type β-Lactamases to Cefiderocol Resistance in Acinetobacter baumannii
- (2021) Laurent Poirel et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- KPC-Mediated Resistance to Ceftazidime-Avibactam and Collateral Effects in Klebsiella pneumoniae
- (2021) Jacqueline Findlay et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects
- (2021) Gabriele Bianco et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- KPC-50 confers resistance to ceftazidime-avibactam associated with reduced carbapenemase activity
- (2020) Laurent Poirel et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- KPC-53, a KPC-3 variant of clinical origin associated with reduced susceptibility to ceftazidime-avibactam
- (2020) Vincenzo Di Pilato et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014)
- (2020) Naoki Kohira et al. Journal of Global Antimicrobial Resistance
- Ceftazidime/avibactam resistance associated with L169P mutation in the omega loop of KPC-2
- (2019) Peera Hemarajata et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Molecular and phenotypical characterization of two cases of antibiotic-driven ceftazidime-avibactam resistance in blaKPC-3-harboring Klebsiella pneumoniae
- (2019) Carolina Venditti et al. Infection and Drug Resistance
- Phenotypic, biochemical and genetic analysis of KPC-41, a KPC-3 variant conferring resistance to ceftazidime-avibactam and exhibiting reduced carbapenemase activity
- (2019) Linda Mueller et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- CTX-M-33, a CTX-M-15 derivative conferring reduced susceptibility to carbapenems
- (2019) Laurent Poirel et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin
- (2019) Takafumi Sato et al. CLINICAL INFECTIOUS DISEASES
- Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections
- (2018) Ryan K. Shields et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Klebsiella pneumoniae Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β-Lactamase Protein Engineering
- (2017) Melissa D. Barnes et al. mBio
- Global Dissemination ofblaKPCinto Bacterial Species beyond Klebsiella pneumoniae andIn VitroSusceptibility to Ceftazidime-Avibactam and Aztreonam-Avibactam
- (2016) Krystyna M. Kazmierczak et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne bla KPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections
- (2016) Ryan K. Shields et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms
- (2016) Roopali Sharma et al. CLINICAL THERAPEUTICS
- In VitroAntimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains
- (2015) Naoki Kohira et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroSelection of Ceftazidime-Avibactam Resistance in Enterobacteriaceae with KPC-3 Carbapenemase
- (2015) David M. Livermore et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination
- (2013) George G. Zhanel et al. DRUGS
- Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases
- (2013) L Silvia Munoz-Price et al. LANCET INFECTIOUS DISEASES
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started